As a federal court in Texas hears a case pitting the FDA versus compounders who want to continue to manufacture cheaper knockoff versions of popular weight loss drugs, Novo Nordisk will not have to | A federal district court in Texas will allow Novo Nordisk to intervene in a lawsuit pitting compounders against the FDA.

Two recent documents—one from the FDA, the other from a commission organized by The Lancet Diabetes & Endocrinology—indicate an evolving mindset toward treating obesity as a chronic disease.

Minnesota lawmakers are once again calling on insurance companies to cover anti-obesity medications like Ozempic and Wegovy as more Americans flock to the drugs to help lose weight.

Eli Lilly has reduced the prices of certain Zepbound vials and introduced higher-dose options, making the weight-loss drug more accessible for some patients.

Pfizer on Thursday named James List as the head of the drugmaker's Internal Medicine portfolio, where he will oversee the development of heart disease and obesity medicines.

Obesity and pharmacology experts are warning about hidden safety risks and efficacy issues for many types of medications in people with obesity.

As drugmakers Novo Nordisk and Eli Lilly struggled to keep up with enormous demand for their diabetes and obesity drugs, the FDA designated their medicines in shortage in 2022 — and kept them there. That made it possible for pharmacies to craft their own ...

Novo Nordisk has launched a direct-to-consumer (DTC) option for uninsured or under-insured people wanting to access its GLP-1 agonist weight-loss drug Wegovy, cutting the drug's price in half to $499 per month for those paying out-of-pocket.

More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.

A study published on Tuesday in 'The Lancet' warns of the escalation of the obesity and overweight pandemic if no action is taken to reverse the trend. The increase would particularly affect Asia and Africa.